Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review - K - 2022 - Journal of Medical Virology - Wiley Online Library
新型コロナウイルス感染症に関する 国内外の研究開発動向について
新型コロナウイルス感染症に関する 国内外の研究開発動向について
Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2: Molecular Therapy - Methods & Clinical Development
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes | Nature Communications
Rapid characterization of spike variants via mammalian cell surface display - ScienceDirect
Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections | ACS Applied Bio Materials
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern | EMBO reports
Frontiers | Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments | ACS Applied Bio Materials
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface | Nature Communications
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma - Wang - 2020 - Cancer Medicine - Wiley Online Library
Rapid characterization of spike variants via mammalian cell surface display | bioRxiv
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany - The Lancet Regional Health – Europe
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine
新型コロナウイルス感染症に関する 国内外の研究開発動向について
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants | Nature Communications
ACWI ex JAPAN ex CHINA A 2022 May SAIR Constituent
Monoclonal antibody therapies against SARS-CoV-2 - The Lancet Infectious Diseases
新型コロナウイルス感染症に関する 国内外の研究開発動向について
Cancers | Free Full-Text | STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy | HTML
Biophysical fitness landscape of the SARS-CoV-2 Delta variant receptor binding domain | bioRxiv
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion | Nature
Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections | ACS Applied Bio Materials
Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review - K - 2022 - Journal of Medical Virology - Wiley Online Library
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates | Science Translational Medicine
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern | EMBO reports
An Analysis of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Preclinical Use | ACS Nano
